Therapeutic approaches directed toward a single pathway or single target such as AR antagonism or prostate-specific membrane antigen radioligand therapy may potently inhibit specific disease subtypes but are unlikely to overcome the heterogeneity commonly seen in advanced prostate cancer (49). The gene discussed is FOLH1; the disease is prostate carcinoma.